ACAD stock news

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session. A live webcast of ACADIA’s presentation Read more
Is (ACAD) Outperforming Other Medical Stocks This Year? Read more
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA. “Stephanie brings extensive ex Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc. Read more
Drug-trial news sent Aurinia and Acadia Pharmaceuticals soaring this morning and Sage Pharmaceuticals tumbling in early trading. Read more
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today presented positive top-line results from its Phase 3 HARMONY study at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California. HARMONY was a double-blind, placebo-controlled, relapse prevention study in 392 patients evaluating pimavanserin for the treatment of dementia-related psychosis. Pimavanserin met the primary endpoint of the study and was stopped at the pre-pl Read more
With the holiday season kicking off, investors are shopping the Street for growth stocks. Stocks of this kind have a clear runway for growth, capable of delivering massive returns in the years to come. No wonder they are topping wish lists. However, in a year that has seen the market reach record highs, tracking down these names is becoming harder and harder to do. But don’t sound the alarm bells just yet. Wall Street pros remind investors that stocks with outsized growth prospects are still out there. In an attempt to lock down these compelling investment opportunities, we turned to TipRanks. The platform’s Stock Screener tool was able to scan the Street for the crème-de-la-crème. We mean the tickers offering up serious upside potential from current levels. Let’s get started. GDS Holdings Ltd ( GDS ) At a 103% year-to-date gain, all eyes are on GDS Holdings. This combined with a solid Q3 performance and strong long-term growth narrative has made the Chinese data center developer and operator a must-have name among several analysts. Read more
Bulletin from annual shareholders' meeting of AcadeMedia AB The following resolutions were passed at AcadeMedia's annual shareholders' meeting held today, on 26 November, 2019, in… Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) (Guggenheim initiated coverage of stock with Buy rating and $50 price target) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) (announced achievement of enrollment target in a Phase 3 trial of drug to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioNTech SE – ADR (NASDAQ: BNTX ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Cue Biopharma Inc (NASDAQ: CUE ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Epizyme Inc (NASDAQ: EPZM ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Globus Medical Inc (NYSE: GMED ) Halozyme Therapeutics, Inc. Read more
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced positive top-line results from its ADVANCE study, a 26-week, randomized, double-blind, placebo-controlled study in 403 patients. ADVANCE evaluated the efficacy and safety of adjunctive pimavanserin treatment in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with their existing antipsychotic treatment. No drug is approved by the FDA for t Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amgen, Inc. (NASDAQ: AMGN ) (raised full-year guidance following completion of Otezla purchase from Celgene) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cue Biopharma Inc (NASDAQ: CUE ) Epizyme Inc (NASDAQ: EPZM ) Kamada Ltd. (NASDAQ: KMDA ) Kodiak Sciences Inc (NASDAQ: KOD ) Molecular Templates Inc (NASDAQ: MTEM ) Recro Pharma Inc (NASDAQ: REPH ) (completed spin-off of Baudax Bio in a bid to a become a pure play CDMO) Down In The Dumps (Biotech stocks that hit 52-week lows on Nov. 21.) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) (received European approval for its Rhokiinsa 0.02% for the reduction of elevated intraocular pressure) Affimed NV (NASDAQ: AFMD ) Anixa Biosciences Inc (NASDAQ: ANIX ) CareDx Inc (NASDAQ: CDNA ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Genprex Inc (NASDAQ: GNPX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Interpace Biosciences Inc (NASDAQ: IDXG ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its previously announced common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) MacroGenics Inc (NASDAQ: MGNX ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) Neon Therapeutics Inc (NASDAQ: NTGN ) (announced a changed focus and the elimination of 24% of workforce) Novavax, Inc. (NASDAQ: NVAX ) Nuvectra Corp (NASDAQ: NVTR ) Onconova Therapeutics … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. Read more
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […] Read more
Does Acadia Pharmaceuticals (ACAD) have what it takes to be a top stock pick for momentum investors? Let's find out. Read more
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to Serge Stankovic, M.D., M.S.P.H., ACADIA’s President and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities. “I am very excited to welcome Ponni to our executive team Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT